ChromaDex Announces $7 Million Private Placement of Common Stock

Tailwinds' Take: continued strategic interest in CDXC bodes well for future market acceptance of Tru Niagen. Revenues beat last Q and are in a...

Recapping The Week That Was…And Looking Towards Next

This was a very hectic week in the market, with major swings in the indexes and in our universe of smaller companies. Earnings season...

ChromaDex Corporation Reports Second Quarter 2019 Financial Results

Tailwinds' Take: great incremental growth. LOS ANGELES, Aug. 07, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today reported second quarter 2019 financial results. “We successfully continue...

A Shallow Dive From The Deep South

In what is shaping up as a never-ending quest to provide newsletter coverage from anyplace not named "home", this week's letter comes from Raleigh,...

ChromaDex Corporation Reports First Quarter 2019 Financial Results

First Quarter 2019 Highlights vs. First Quarter 2018 Strong start to the year with $10.0 million of net sales, higher gross margins and increased marketing efficiency ...

ChromaDex Announces $10 Million Issuance of Convertible Notes

LOS ANGELES, May 09, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it has entered into a note purchase agreement for the sale of $10.0 million of convertible...

ChromaDex Drives Global Expansion Strategy for TRU NIAGEN® with Specialty Retail Launch and Expanded...

LOS ANGELES, April 15, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today the latest milestone in its global expansion strategy for TRU NIAGEN®, with a strategic deal...

New Study Deepens Research Into the Potential Cardiovascular Health Benefits of Supplementation with Nicotinamide...

LOS ANGELES, April 09, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a new preclinical study showed that supplementation with the unique B3 vitamin...

ChromaDex Corporation Reports 2018 Financial Results

Fourth Quarter 2018 Highlights vs. Fourth Quarter 2017 Entered into a global license and supply agreement with Nestlé Health Science (“NHSc”), which provides NHSc...

ChromaDex Corp. and Nestlé Health Science Enter Global Commercial License and Supply Agreement for...

Tailwinds' Take: this press release has a big "WOW" factor. If the market was looking for validation of Tru Niagen, Nestle can...

LD Micro Recap

This week saw several extraordinary events come together simultaneously. On Tuesday the market dipped to the 4th largest...

ChromaDex Corporation Reports Third Quarter 2018 Financial Results

hird Quarter 2018 Highlights vs. Third Quarter 2017 Net sales up 33%, fueled by growth of TRU NIAGEN®, which increased by 97%; TRU NIAGEN...

ChromaDex: Is Elysium About To Get In Trouble?

ChromaDex (CDX) is known by investors as the manufacturer of Nicotinamide Riboside, more commonly referred to as NR, an anti-aging nutraceutical. They are also...

October Review, Earnings Preview

October has a reputation for being a bad month to own stocks. For the current generation of investors, this reputation was earned primarily from...

CDXC Takes A Hit On Frost & Honig’s SEC Troubles

Shares in Chromadex were hit hard today, losing over 9% and closing at levels not seen since early July. This action in the stock...

ChromaDex Corporation Reports Second Quarter 2018 Financial Results

IRVINE, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN®...

ChromaDex and Watsons Expand TRU NIAGEN® Retail Partnership Through 2021

IRVINE, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and...

Fourth Published Clinical Trial Confirms Long-Term Safety of NIAGEN® Supplementation at High Doses and...

IRVINE, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that results from...

TRU NIAGEN® to be featured at the American Society for Nutrition’s Annual Meeting

Tailwinds' Take: CDXC stock has been weak with a combination of lack of news and forecasted sales not picking up until Q3 weighing on...

With Earnings Season Over, Which Stocks Surprised Us?

Quarterly earnings season is the four times each year in which companies give investors an inside look as to what's going on. They not...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.